PDL BioPharma, Inc. Appoints Christopher L. Stone as Vice President, General Counsel and Secretary

INCLINE VILLAGE, NV--(Marketwire - February 02, 2009) - PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its board of directors has appointed Christopher L. Stone, J.D., as vice president, general counsel and secretary. Stone brings more than 18 years of legal experience to the role.

“Christopher brings extensive intellectual property and biotechnology experience to PDL and we’re pleased to have him join our team,” said John McLaughlin, president and chief executive officer of PDL. “He has a wealth of experience managing intellectual property litigation.”

Previously, Stone served as a vice president of legal affairs and corporate secretary at LS9, an advanced biofuels development company, where his work included a focus on intellectual property protection and licensing. From 2005-2006, he was vice president of intellectual assets USA at Danisco A/S, a global producer of food ingredients, enzymes and bio-based solutions. From 1994-2005, Stone was vice president of intellectual property and general patent counsel at Genencor International, a biotechnology company which was acquired by Danisco in 2005. At Genencor, he handled all intellectual property matters, including developing and implementing an overall strategy for its domestic and international patent estate of approximately 3,700 patents and patent applications, as well as managed multiple litigation and interference proceedings, and numerous European patent oppositions.

Stone began his law career as an associate attorney at Willian Brinks Hofer Gilson & Lione, where he specialized in patent and trade secret court actions and prosecuted biotechnology patent applications before the United States Patent & Trademarks Office. Stone received a J.D. from the National Law Center at George Washington University and a B.S. in Biochemistry from the University of Massachusetts. He is a member of the District of Columbia Bar and California Bar, and was admitted to practice before the United States Patent & Trademark Office in 1992.

About PDL BioPharma

PDL BioPharma was a pioneer in the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. The company is focused on maximizing the value of its antibody humanization patents and related assets. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.